Aceragen is a rare disease biopharmaceutical company that is dedicated to improving the lives of patients through biotechnology. They focus on tackling rare and orphan diseases that often have no approved treatments, with the aim of developing important therapies to help patients in need. The needs of patients suffering from unserved or under-served rare diseases form the driving force behind Aceragen's mission.

Their pipeline includes potential treatments for various rare diseases such as Farber Disease, a lysosomal storage disorder that leads to progressive disease and premature death, Melioidosis, a life-threatening infectious disease, and Cystic Fibrosis, a genetic disease that causes lung infections and declining lung function. Aceragen's commitment to making a difference in the lives of patients with rare diseases is reflected in their late-stage rare disease portfolio and their multiple anticipated clinical milestones in 2023. By delivering innovative therapies, Aceragen strives to provide a better life for patients facing these extraordinary health challenges